ADAG: 1 Funds Holding, Catalyst in 64d | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›Adagene Inc. (ADAG)

Adagene Inc.

ADAG

Held by 1 specialist biotech fund

1 fund opened new positions. Next phase2 readout (ADG126): Oct 2026. Short interest: 3.7% of float.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

3.0/10

1 fund opened new positions

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

●●

No recent insider activity●●

Phase2 readout in 64 days●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

1 specialist fund hold ADAG with a Phase 2 in 64 days for ADG126 (Advanced/Metastatic Solid Tumors)

Deerfield Management

Fund Holdings

Deerfield ManagementNew

Short Interest

Short Shares

2.11M

Change

-3.6%

Days to Cover

9.5

% of Float

3.7%

Settlement

Aug 14, 2026

Short interest over 3 periods

Catalysts

Phase 2Q4 2026ADG126Advanced/Metastatic Solid TumorsNCT05405595

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Deerfield ManagementNEW POSITIONAug 14, 2026

Start free trialfor share counts, dollar values & AI analysis

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

SION1 fund SGP1 fund STOK1 fund GPCR1 fund SNDX1 fund TNGX1 fund TOIIW1 fund TYRA1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer